Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 913-921

  Al Ejeh, Fares ^a   Shi, Wei ^a   Miranda, Mariska ^a   Simpson, Peter T ^b   Vargas, Ana Cristina ^b   Song, Sarah ^b,c   Wiegmans, Adrian P ^a   Swarbrick, Alex ^d,e   Welm, Alana L ^f   Brown, Michael P ^g,h   Chenevix Trench, Georgia ^a   Lakhani, Sunil R ^b,c,i   Khanna, Kum Kum ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Combination therapy; EGFR; PARP inhibitor; Radioimmunotherapy; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CD24 ANTIGEN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY LU 177; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RUCAPARIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT;

COMBINATION THERAPY; EGFR; PARP INHIBITOR; RADIOIMMUNOTHERAPY; TRIPLE-NEGATIVE BREAST CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; FEMALE; LUTETIUM; MICE; NEOPLASM METASTASIS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER;

EID: 84878644301     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111534     Document Type: Article

References (40)

1. Reeder-Hayes KE, Carey LA, Sikov WM. Clinical trials in triple negative breast cancer. Breast Dis. 2010;32:123-136.
2. Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010;10:507-521.
3. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376. (Pubitemid 351413917)
4. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15:2302-2310.
5. Liu D, He J, Yuan Z, et al. EGFR expression correlates with decreased diseasefree survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29:401-405.
6. Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G. EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet. 2010;203:222-229.
7. Bild AH, Parker JS, Gustafson AM, et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009;11:R55-R64.
8. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007;8:258-276.
9. Irshad S, Ashworth A, Tutt A. Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther. 2011;11:1243-1251.
10. Al-Ejeh F, Darby JM, Tsopelas C, Smyth D, Manavis J, Brown MP. APOMAB, a La-specific monoclonal antibody detects the apoptotic tumor response to lifeprolonging and DNA-damaging chemotherapy. PLoS ONE. 2009;4:e4558-e4568.
11. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10:R25-R37.
12. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res. 2007;9:303-305.
13. Louderbough JM, Brown JA, Nagle RB, Schroeder JA. CD44 promotes epithelial mammary gland development and exhibits altered localization during cancer progression. Genes Cancer. 2011;2:771-781.
14. Milenic DE, Wong KJ, Baidoo KE, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm. 2008;23:619-631.
15. 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS ONE. 2011;6:e18198-e18206.
16. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst. 1989;81:1616-1625. (Pubitemid 19264044)
17. Liu Z, Liu Y, Jia B, et al. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Ylabeled fully human antibody panitumumab. Mol Cancer Ther. 2010;9:2297-2308.
18. Capote AR, Gonz ález JE, Rodríguez- Vera L, López A, Ramírez BS, Hidalgo GG. Pharmacokinetics and biodistribution study of 7A7 antimouse epidermal growth factor receptor monoclonal antibody and its F (ab′)2 fragment in an immunocompetent mouse model. ISRN Pharmacol. In press.
19. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97-104.
20. Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med. 1989;30:1636-1645. (Pubitemid 19250718)
21. Li L, Quang TS, Gracely EJ, et al. A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010;113:192-198.
22. Al-Ejeh F, Smart CE, Morrison BJ, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32:650-658.
23. Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64:937-946.
24. Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53-R64.
25. Wobus M, Rangwala R, Sheyn I, et al. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol. 2002;10:34-39. (Pubitemid 34178274)
26. Pályi-Krekk Z, Barok M, Kovacs T, et al. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett. 2008;263:231-242.
27. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672-679.
28. Shi Y, Zhang F, Cao M, et al. The role of EGFR MAbs C225 in breast cancer stem cells [abstract]. J Clin Oncol. 2009;27(suppl):e22093.
29. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862-867.
30. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2011;226:2316-2328.
31. de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183-192.
32. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 2011;71:1103-1114.
33. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005;76:157-161. (Pubitemid 41725442)
34. Friedmann BJ, Caplin M, Savic B, et al. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther. 2006;5:209-218.
35. Ko JC, Hong JH, Wang LH, et al. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol Cancer Ther. 2008;7:3632-3641.
36. Ko JC, Ciou SC, Cheng CM, et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis. 2008;29:1448-1458.
37. Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008;68:9141-9146.
38. Al-Ejeh F, Brown MP. Combined modality therapy: relevance for targeted radionuclide therapy In: Speer TW, ed. Targeted Radionuclide Therapy. Philadelphia, PA: Lippincott Williams and Wilkins;2010:220-235.
39. Page P, Yang LX. Novel chemoradiosensitizers for cancer therapy. Anticancer Res. 2010;30:3675-3682.
40. Al-Ejeh F, Darby JM, Brown MP. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS ONE. 2009;4:e4630-e4642.